AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26591005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24630905 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (2-day program with a half-day follow-up)
Number of subjects: 188
Study 24630905 — intervention group
Group type: COMPARATOR
Intervention: Self-study using a similar content handbook
Number of subjects: 188
Study 22329789 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-choice completion task
Number of subjects: 0
Study 22329789 — intervention group
Group type: EXPERIMENTAL
Intervention: rapid serial visual presentation task
Number of subjects: 0
Study 22329789 — intervention group
Group type: EXPERIMENTAL
Intervention: binary confidence judgments
Number of subjects: 0
Study 20816294 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz appliance (expanded group)
Number of subjects: 28
Study 20816294 — intervention group
Group type: COMPARATOR
Intervention: Schwarz appliance (nonexpanded group)
Number of subjects: 28
Study 19088803 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (50 microg x min‐1 intracoronary infusion)
Number of subjects: 20
Study 19088803 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 20
Study 16227145 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 5016
Study 16227145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5016
Study 12105241 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent proteinuria (UP) >1.0 g/24 h at diagnosis
Number of subjects: 154
Study 12105241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year level of 24-h UP
Number of subjects: 154
Study 12105241 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine (SC) at 1 year
Number of subjects: 154
Study 12105241 — intervention group
Group type: EXPERIMENTAL
Intervention: SC trends (slopes) over the prior year
Number of subjects: 154
Study 12105241 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 154
Study 12105241 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 154
Study 10202242 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose (TD) gadolinium (Gd) enhanced MRI
Number of subjects: 10
Study 10202242 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) gadolinium (Gd) enhanced MRI
Number of subjects: 10
Study 10202242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Gd doses during clinical relapses
Number of subjects: 10
Study 10202242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Gd doses after clinical relapses
Number of subjects: 10
Study 9304380 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose concentration
Number of subjects: 21
Study 9304380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructosamine (FA)
Number of subjects: 21
Study 9304380 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin (HbA1)
Number of subjects: 21
Study 2185495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression (IPC)
Number of subjects: 30
Study 2185495 — intervention group
Group type: EXPERIMENTAL
Intervention: High Voltage Pulsed Current (HVPC)
Number of subjects: 30
Study 2185495 — intervention group
Group type: COMPARATOR
Intervention: Placebo-HVPC
Number of subjects: 30
Study 121483 — intervention group
Group type: EXPERIMENTAL
Intervention: Home IPPB therapy (at least 1 to 2 hours daily through a mouthpiece)
Number of subjects: 0
Study 121483 — intervention group
Group type: COMPARATOR
Intervention: Control group (without IPPB therapy)
Number of subjects: 0
Study 31050851 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention (8 weeks, 3 sessions per week, 30 minutes each)
Number of subjects: 51
Study 31050851 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 51
Study 28991063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.625, 1.0, 1.5, 2.5, 4.0, or 6.25 mg)
Number of subjects: 270
Study 28991063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.625, 1.0, 1.5, 2.5, 4.0, or 6.25 mg)
Number of subjects: 270
Study 28991063 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.625, 1.0, 1.5, 2.5, 4.0, or 6.25 mg)
Number of subjects: 270
Study 24963079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training group (N = 11)
Number of subjects: 32
Study 24963079 — intervention group
Group type: COMPARATOR
Intervention: Computer games group (N = 11)
Number of subjects: 32
Study 24963079 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (N = 10)
Number of subjects: 32
Study 23804013 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Number of subjects: 49
Study 23804013 — intervention group
Group type: COMPARATOR
Intervention: Time Management (Control)
Number of subjects: 49
Study 21610364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 45
Study 21610364 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 45
Study 21610364 — intervention group
Group type: COMPARATOR
Intervention: Control (routine surgical procedures)
Number of subjects: 45
Study 19309330 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 4
Study 19309330 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 4
Study 19309330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 17108800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsiflexor group
Number of subjects: 12
Study 17108800 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantarflexor group
Number of subjects: 12
Study 17108800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsi- and plantarflexor group
Number of subjects: 12
Study 17108800 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 12823153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 18
Study 12823153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 18
Study 12823153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 18
Study 12823153 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole capsule 20 mg
Number of subjects: 18
Study 12823153 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole MUPS tablet 20 mg
Number of subjects: 18
Study 12823153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10630921 — intervention group
Group type: EXPERIMENTAL
Intervention: Citizen's Advice Bureau services
Number of subjects: 6
Study 10630921 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 6
Study 8777954 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled heparin (1,000 U.kg‐1)
Number of subjects: 11
Study 8777954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 11
Study 2070526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tube insertion
Number of subjects: 43
Study 2070526 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (control group)
Number of subjects: 43
Study 6573318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 grams as disodium salt, intramuscularly, every 12 hours)
Number of subjects: 0
Study 6573318 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine (0.5% as diluent)
Number of subjects: 0
Study 30696335 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk program (8-month physical activity program)
Number of subjects: 143
Study 30696335 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 143
Study 27824680 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (20 mg)
Number of subjects: 30
Study 27824680 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg)
Number of subjects: 30
Study 25278459 — intervention group
Group type: EXPERIMENTAL
Intervention: High progesterone (mid-luteal) phase with strong mental imagery
Number of subjects: 64
Study 25278459 — intervention group
Group type: EXPERIMENTAL
Intervention: Low progesterone (follicular) phase with strong mental imagery
Number of subjects: 64
Study 25278459 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing sensory features of images
Number of subjects: 64
Study 25278459 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing conceptual characteristics of images
Number of subjects: 64
Study 25278459 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 64
Study 22961196 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) ointment
Number of subjects: 207
Study 22961196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 207
Study 20798660 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (PRO; 3 g protein·kg(‐1) body mass (BM)·d(‐1))
Number of subjects: 2
Study 20798660 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (CON; 1.5 g protein·kg(‐1) BM·d(‐1))
Number of subjects: 2
Study 20798660 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (PRO) during recovery training
Number of subjects: 2
Study 20798660 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (PRO)
Number of subjects: 2
Study 20798660 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (CON)
Number of subjects: 2
Study 19367171 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (two-thirds of the total daily insulin dose required) subcutaneous administration with 5% dextrose solution infusion
Number of subjects: 30
Study 19367171 — intervention group
Group type: COMPARATOR
Intervention: Glucose-insulin-potassium (GIK) infusion (125 ml/h)
Number of subjects: 30
Study 16688803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg bid)
Number of subjects: 83
Study 16688803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 15205242 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial examination of astigmatism
Number of subjects: 522
Study 15205242 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal study of 108 children
Number of subjects: 522
Study 15205242 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of astigmatism
Number of subjects: 522
Study 15205242 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased astigmatism
Number of subjects: 522
Study 11309553 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg orally, 4 times with 12-hour intervals
Number of subjects: 16
Study 9717038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) > or = 40
Number of subjects: 3395
Study 9717038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) 30-40
Number of subjects: 3395
Study 9717038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) 20-30
Number of subjects: 3395
Study 9717038 — intervention group
Group type: COMPARATOR
Intervention: Cardiac Infarction Injury Score (CIIS) < 20
Number of subjects: 3395
Study 9717038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) > or = 40 at 3 year follow-up
Number of subjects: 3395
Study 9717038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) 30-40 at 3 year follow-up
Number of subjects: 3395
Study 9717038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Infarction Injury Score (CIIS) 20-30 at 3 year follow-up
Number of subjects: 3395
Study 7992068 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/etoposide
Number of subjects: 265
Study 7992068 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/etoposide
Number of subjects: 265
Study 2568202 — intervention group
Group type: EXPERIMENTAL
Intervention: bromazepam 1.5 mg bidaily (B)
Number of subjects: 20
Study 2568202 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 100 mg bidaily (L)
Number of subjects: 20
Study 2568202 — intervention group
Group type: COMPARATOR
Intervention: placebo bidaily (P1)
Number of subjects: 20
Study 2568202 — intervention group
Group type: COMPARATOR
Intervention: placebo bidaily (P2)
Number of subjects: 20
Study 31124504 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laser treatment followed by additional posterior retinal laser treatment
Number of subjects: 20
Study 31124504 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser treatment (control group)
Number of subjects: 20
Study 28891545 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C levels in SCA patients
Number of subjects: 50
Study 28891545 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) levels in SCA patients
Number of subjects: 50
Study 28891545 — intervention group
Group type: COMPARATOR
Intervention: Protein C levels in control group
Number of subjects: 50
Study 28891545 — intervention group
Group type: COMPARATOR
Intervention: Antithrombin (AT) levels in control group
Number of subjects: 50
Study 25065959 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) PLT prophylaxis
Number of subjects: 1102
Study 25065959 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose (MD) PLT prophylaxis
Number of subjects: 1102
Study 25065959 — intervention group
Group type: COMPARATOR
Intervention: Low-dose (LD) PLT prophylaxis
Number of subjects: 1102
Study 25065959 — intervention group
Group type: EXPERIMENTAL
Intervention: All PLT transfusions
Number of subjects: 1102
Study 25065959 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent PLT transfusions
Number of subjects: 1102
Study 23062105 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Irrigation (PUI) with 0.04 taper
Number of subjects: 68
Study 23062105 — intervention group
Group type: COMPARATOR
Intervention: Sonic Irrigation (SI) with 0.04 taper
Number of subjects: 68
Study 23062105 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Irrigation (PUI) with 0.08 taper
Number of subjects: 68
Study 23062105 — intervention group
Group type: COMPARATOR
Intervention: Sonic Irrigation (SI) with 0.08 taper
Number of subjects: 68
Study 21996202 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitors with steroids
Number of subjects: 115
Study 21996202 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcineurin inhibitor, mycophenolate mofetil or sodium plus steroids)
Number of subjects: 115
Study 18488439 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (n = 40) participated in a 14-week rehabilitation program (3 h/week, 1.5 h of education and exercise and 1.5 h of cycling)
Number of subjects: 80
Study 18488439 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40) reviewed routinely as medical outpatients
Number of subjects: 80
Study 16508333 — intervention group
Group type: EXPERIMENTAL
Intervention: SLITone (1,000 STU per milliliter)
Number of subjects: 47
Study 16508333 — intervention group
Group type: COMPARATOR
Intervention: 10 IR solution
Number of subjects: 47
Study 16508333 — intervention group
Group type: COMPARATOR
Intervention: 100 IR solution
Number of subjects: 47
Study 16508333 — intervention group
Group type: COMPARATOR
Intervention: 300 IR solution
Number of subjects: 47
Study 12495136 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (exact details not available)
Number of subjects: 0
Study 12495136 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional group-sequential phase III designs)
Number of subjects: 0
Study 10428734 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 43
Study 10428734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7481533 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance every 2 years (group A)
Number of subjects: 0
Study 7481533 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance every 4 years (group B)
Number of subjects: 0
Study 2105872 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasil (0.075 mg LNG, 0.040 mg EE2)
Number of subjects: 24
Study 2105872 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinordiol (0.075 mg LNG, 0.040 mg EE2)
Number of subjects: 24
Study 2105872 — intervention group
Group type: COMPARATOR
Intervention: Hydroalcoholic solution (0.075 mg LNG, 0.040 mg EE2)
Number of subjects: 24
Study 2105872 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations (Triphasil, Trinordiol, Hydroalcoholic solution)
Number of subjects: 24
Study 373956 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment center selection criteria
Number of subjects: 0
Study 373956 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in eligibility criteria and procedural requirements
Number of subjects: 0
Study 373956 — intervention group
Group type: COMPARATOR
Intervention: Prior experience of clinic staff in clinical trials
Number of subjects: 0
Study 373956 — intervention group
Group type: COMPARATOR
Intervention: Population density and annual rate of cholecystectomy
Number of subjects: 0
Study 373956 — intervention group
Group type: COMPARATOR
Intervention: Rating given to a center at the time of selection
Number of subjects: 0
Study 6833462 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐4 mg micronized estradiol given orally
Number of subjects: 38
Study 6833462 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg estradiol orally
Number of subjects: 38
Study 6833462 — intervention group
Group type: COMPARATOR
Intervention: 3 mg estradiol applied cutaneously
Number of subjects: 38
Study 31571571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous, microfragmented adipose tissue
Number of subjects: 20
Study 30538180 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat group (15% total energy)
Number of subjects: 109
Study 30538180 — intervention group
Group type: COMPARATOR
Intervention: Low saturated fat group (7% total energy)
Number of subjects: 109
Study 30538180 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat protein source (12% energy)
Number of subjects: 109
Study 30538180 — intervention group
Group type: EXPERIMENTAL
Intervention: White meat protein source (12% energy)
Number of subjects: 109
Study 30538180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmeat protein source (16% energy)
Number of subjects: 109
Study 30538180 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alpha diversity
Number of subjects: 109
Study 27748307 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBHI)
Number of subjects: 100
Study 25040840 — intervention group
Group type: COMPARATOR
Intervention: 0.2% plain ropivacaine 0.75 ml·kg(‐1)
Number of subjects: 80
Study 25040840 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 0.5 μg·kg(‐1) with 0.2% ropivacaine 0.75 ml·kg(‐1)
Number of subjects: 80
Study 25040840 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1.0 μg·kg(‐1) with 0.2% ropivacaine 0.75 ml·kg(‐1)
Number of subjects: 80
Study 25040840 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1.5 μg·kg(‐1) with 0.2% ropivacaine 0.75 ml·kg(‐1)
Number of subjects: 80
Study 22246148 — intervention group
Group type: EXPERIMENTAL
Intervention: PIES intervention with tailoring
Number of subjects: 72
Study 22246148 — intervention group
Group type: EXPERIMENTAL
Intervention: PIES intervention without tailoring
Number of subjects: 72
Study 22246148 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard National Cancer Institute brochures)
Number of subjects: 72
Study 20219398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo treatment for back pain patients with low or moderate levels of catastrophizing
Number of subjects: 0
Study 20219398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo treatment for back pain patients with high levels of catastrophizing
Number of subjects: 0
Study 20219398 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 0
Study 20219398 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0
Study 20219398 — intervention group
Group type: EXPERIMENTAL
Intervention: Low change participants
Number of subjects: 0
Study 17347859 — intervention group
Group type: EXPERIMENTAL
Intervention: Outox (250 ml)
Number of subjects: 30
Study 17347859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml)
Number of subjects: 30
Study 16248468 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI) training (90% of 1RM)
Number of subjects: 64
Study 16248468 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity (MI) training (70% of 1RM)
Number of subjects: 64
Study 16248468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Intensity (LI) training (50% of 1RM)
Number of subjects: 64
Study 16248468 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 64
Study 11914748 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10) 200 mg orally for 12 weeks
Number of subjects: 40
Study 11914748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11914748 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10)
Number of subjects: 40
Study 10414394 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg by Turbuhaler)
Number of subjects: 17
Study 10414394 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (50 microg by Turbuhaler)
Number of subjects: 17
Study 10414394 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg by Diskhaler)
Number of subjects: 17
Study 10414394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9422205 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytic HLA-DR expression measurement in patients after elective neurosurgery
Number of subjects: 67
Study 9422205 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytic HLA-DR expression measurement in dermatological patients receiving high dose systemic steroids
Number of subjects: 67
Study 2137279 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nicorandil
Number of subjects: 9
Study 2137279 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nicorandil
Number of subjects: 9
Study 2137279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9